AstraZeneca Launches Phase 3 Study of NSCLC Immunotherapy | Lung Cancer Dispatch |

"On the heels of rebuking merger offers from Pfizer, AstraZeneca announced in a press release it is moving forward with the phase 3 PACIFIC trial of a lung cancer immunotherapy drug.

"The drug, MEDI4736, is a human monoclonal antibody directed against programmed death ligand 1 (PD-L1). The drug, still in development, targets the PD-L1/PD-1 pathway for the treatment of non–small cell lung cancer (NSCLC) by blocking signals which allow PD-L1 to escape detection by the immune system."

Editor's note: MEDI4736 is an immunotherapy drug that is meant to boost a patient's own immune system to fight cancer. Learn more about immunotherapy and clinical trials here.